ARIAD Pharmaceuticals Inc. (ARIA) +0.02

Trade ARIA
NOW!
Last Trade:3.19Short Ratio:5.30
Last Trade Time:4:00pmDay Range:3.18 - 3.29
Ask:Year Range:1.15 - 3.92
Bid:3.14One Year Target:5.17
Open:3.23Exchange:NGM
Volume:3690463EBITDA:-66.9M
Prev. Close:3.17Market Cap:347.6M
50 Day Moving:2.6631Div Yield:
200 day moving:2.3545PE:

Benzinga’s Top Downgrades (ASTI , WAB, ARIA, WNS, WNI)

Ascent Solar Technologies Inc (NASDAQ: ASTI) was downgraded by Ardour Capital from “hold” to “reduce.” ASTI closed at $3.78 yesterday. ASTI has a 52-week trading range of $2.90-$8.83. Read more about this company here.

US Stock Market Notable Downgrades are PLCM, IPXL, WNI, FEN, VIVO, ARIA

(EMAILWIRE.COM, March 18, 2010 ) Dallas, Tx - Polycom, Inc. (NASDAQ:PLCM) fell 2.29% to $32.38 after BofA/Merrill Lynch downgraded their rating on the company's share from Buy to Neutral and raised the price target by $3 to $35.

Notable Healthcare Stocks Rating are WNI, ARIA, PETS, MDTH

(EMAILWIRE.COM, March 18, 2010 ) Dallas, Tx - B. Riley & Co have downgraded shares of Schiff Nutrition International Inc. (NYSE:WNI) from Buy to Neutral. Shares of WNI are trading down 1.14% to $9.51. Subscribe to daily free stock newsletter by visiting: http://www.PennyStockPickReport.com

Biotech Stocks Surge in Morning Session (NEXM, MDCO, ARIA, ARNA, JAZZ, MBRK, INCY, QCOR)

(EMAILWIRE.COM, March 17, 2010 ) Dallas, Tx - NexMed, Inc.

US Stocks Closed Mixed on Earnings (CFSG, ARIA, DSW)

(EMAILWIRE.COM, March 17, 2010 ) Dallas, Tx - China Fire & Security Group, Inc. (NASDAQ:CFSG) lost 7.75% to $14.28. The company reported a decrease in fourth quarter earnings, reflecting reduced revenue and gross margin, as well as the 12.5% income tax on its major operating subsidiary in China.

Ariad Pharmaceuticals Upward Momentum Looks to Continue (ARIA)

SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ: ARIA) on November 09, 2009 at $2.42. In approximately 4 months, Ariad Pharmaceuticals has returned 41.3% as of today's recent price of $3.42.

Ariad Pharma Reports Inline Loss, Will Offer Guidance After Merck Agreement Finalized (ARIA)

3/16/2010-Ariad Pharmaceuticals (NASDAQ: ARIA) reported a Q4 loss of $0.17 per share, in line with consensus estimates. Revenues for the quarter fell 15.4% year-over-year to $2.2 million, missing consensus estimates of $2.3 million.

ARIAD Reports Development Progress and Fourth Quarter and Year-End 2009 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2009 and provided an update on corporate developments. Phase 3 Sarcoma Data in 2010

US Stocks Down After Earnings (DSW, CFSG, ARIA)

(EMAILWIRE.COM, March 16, 2010 ) Dallas, Tx - DSW Inc. (NYSE:DSW) is down 7.85% to $27.12. The company reported a profit for the fourth quarter compared to a loss last year, reflecting higher revenues. For the quarter, net income was $13.40 million, compared with a net loss of $7.52 million last year.

ARIAD to Present at the Barclays Capital Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA